RU2352628C2 - Новые штаммы бифидобактерий, обладающие способностью продуцировать глутамин - Google Patents
Новые штаммы бифидобактерий, обладающие способностью продуцировать глутамин Download PDFInfo
- Publication number
- RU2352628C2 RU2352628C2 RU2005127331/13A RU2005127331A RU2352628C2 RU 2352628 C2 RU2352628 C2 RU 2352628C2 RU 2005127331/13 A RU2005127331/13 A RU 2005127331/13A RU 2005127331 A RU2005127331 A RU 2005127331A RU 2352628 C2 RU2352628 C2 RU 2352628C2
- Authority
- RU
- Russia
- Prior art keywords
- dsm
- patients
- strain
- cure
- bifidobacterium infantis
- Prior art date
Links
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 241000186000 Bifidobacterium Species 0.000 title claims description 47
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims abstract description 73
- 229940004120 bifidobacterium infantis Drugs 0.000 claims abstract description 49
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 15
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 14
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 12
- 208000010718 Multiple Organ Failure Diseases 0.000 claims abstract 12
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims abstract 12
- 239000012634 fragment Substances 0.000 claims description 50
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 239000004475 Arginine Substances 0.000 claims description 28
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 28
- 239000013611 chromosomal DNA Substances 0.000 claims description 24
- 238000009396 hybridization Methods 0.000 claims description 21
- 239000000523 sample Substances 0.000 claims description 18
- 238000001356 surgical procedure Methods 0.000 claims description 17
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 16
- 241000588724 Escherichia coli Species 0.000 claims description 15
- 244000199866 Lactobacillus casei Species 0.000 claims description 15
- 238000002105 Southern blotting Methods 0.000 claims description 15
- 238000002512 chemotherapy Methods 0.000 claims description 15
- 230000002980 postoperative effect Effects 0.000 claims description 13
- 238000000926 separation method Methods 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 12
- 238000003776 cleavage reaction Methods 0.000 claims description 11
- 230000007017 scission Effects 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 10
- 208000037112 Intestinal Failure Diseases 0.000 claims description 8
- 241000186660 Lactobacillus Species 0.000 claims description 8
- 229910021529 ammonia Inorganic materials 0.000 claims description 8
- 229940039696 lactobacillus Drugs 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 7
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- 235000013325 dietary fiber Nutrition 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000002609 medium Substances 0.000 abstract description 9
- 210000000936 intestine Anatomy 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000001963 growth medium Substances 0.000 abstract description 3
- 210000002429 large intestine Anatomy 0.000 abstract description 2
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 208000034486 Multi-organ failure Diseases 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 235000004554 glutamine Nutrition 0.000 description 44
- 235000009697 arginine Nutrition 0.000 description 25
- 229920001817 Agar Polymers 0.000 description 17
- 239000008272 agar Substances 0.000 description 17
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 16
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 15
- 235000013922 glutamic acid Nutrition 0.000 description 15
- 239000004220 glutamic acid Substances 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 206010009887 colitis Diseases 0.000 description 11
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 9
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 235000013477 citrulline Nutrition 0.000 description 9
- 229960002173 citrulline Drugs 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 235000021395 porridge Nutrition 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 240000006024 Lactobacillus plantarum Species 0.000 description 4
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229940072205 lactobacillus plantarum Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 241000186020 Bifidobacterium dentium Species 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 241000186606 Lactobacillus gasseri Species 0.000 description 3
- 241000186605 Lactobacillus paracasei Species 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 2
- 206010070545 Bacterial translocation Diseases 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical group OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000007375 bacterial translocation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 230000008383 multiple organ dysfunction Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- HPNDBHLITCHRSO-WHFBIAKZSA-N Asp-Ala-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(O)=O HPNDBHLITCHRSO-WHFBIAKZSA-N 0.000 description 1
- 241001655328 Bifidobacteriales Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001468229 Bifidobacterium thermophilum Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- OMRWDMWXRWTQIU-YJRXYDGGSA-N Thr-Tyr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CS)C(=O)O)N)O OMRWDMWXRWTQIU-YJRXYDGGSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0300245-8 | 2003-01-31 | ||
| SE0300245A SE526711C2 (sv) | 2003-01-31 | 2003-01-31 | Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav |
| US44727403P | 2003-02-14 | 2003-02-14 | |
| US60/447,274 | 2003-02-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005127331A RU2005127331A (ru) | 2006-01-27 |
| RU2352628C2 true RU2352628C2 (ru) | 2009-04-20 |
Family
ID=20290264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005127331/13A RU2352628C2 (ru) | 2003-01-31 | 2004-01-27 | Новые штаммы бифидобактерий, обладающие способностью продуцировать глутамин |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7947482B2 (enExample) |
| EP (1) | EP1587913B1 (enExample) |
| JP (1) | JP4540664B2 (enExample) |
| CN (1) | CN100558883C (enExample) |
| AT (1) | ATE496115T1 (enExample) |
| AU (1) | AU2004208084B2 (enExample) |
| BR (1) | BRPI0407176B8 (enExample) |
| CA (1) | CA2514659C (enExample) |
| DE (1) | DE602004031079D1 (enExample) |
| DK (1) | DK1587913T3 (enExample) |
| ES (1) | ES2362496T3 (enExample) |
| PL (1) | PL212096B1 (enExample) |
| RU (1) | RU2352628C2 (enExample) |
| SE (1) | SE526711C2 (enExample) |
| WO (1) | WO2004067731A1 (enExample) |
| ZA (1) | ZA200505777B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5363811B2 (ja) | 2005-09-28 | 2013-12-11 | ノルディスク リバランス アクティーゼルスカブ | 治療エフェクターとしてプロバイオティック細菌と発酵穀物を用いるｉｂｄ及びｉｂｓの治療 |
| EP1951273B1 (en) * | 2005-10-06 | 2014-02-12 | Probi Ab | Use of lactobacillus for treatment of autoimmune diseases |
| WO2012005240A1 (ja) * | 2010-07-05 | 2012-01-12 | 株式会社明治 | 腸内腐敗物質の低減作用を有するビフィズス菌 |
| CL2010001124A1 (es) | 2010-10-14 | 2011-01-21 | Univ De Concepcion 50% Ma Loreto Ormeno 50% | Alimento funcional probiotico que comprende cepas viables de lactobacillus sp.; uso de dicho alimento funcional para contrarestar los efectos colaterales de la quimioterapia. |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| CN103131647B (zh) * | 2011-11-29 | 2017-06-27 | 上海上药信谊药厂有限公司 | 婴儿双歧杆菌及其制剂 |
| IN2014DN07752A (enExample) | 2012-02-29 | 2015-05-15 | Ethicon Endo Surgery Inc | |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| SG10201903823QA (en) | 2014-10-31 | 2019-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
| CN108330166A (zh) * | 2017-09-06 | 2018-07-27 | 深圳市百澳飞生物技术有限公司 | 一种酶制剂的饲用活性评估方法 |
| CN113164526A (zh) | 2018-07-19 | 2021-07-23 | 潘德勒姆治疗公司 | 用于微生物植入的方法和组合物 |
| RU2699967C1 (ru) * | 2018-12-25 | 2019-09-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) | Способ комплексного лечения энтеральной недостаточности у детей с тяжелой термической травмой |
| US11045507B2 (en) | 2019-02-21 | 2021-06-29 | Ewelina Sosnowska-Turek | Bifidobacterium animalis AMT30 strain and the composition containing the strain of Bifidobacterium animalis AMT30 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2112034C1 (ru) * | 1996-12-26 | 1998-05-27 | Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского | Штамм bifidobacterium infantis 73-15, используемый для приготовления бифидосодержащих бактерийных препаратов и продуктов лечебно-диетического питания |
| US6077504A (en) * | 1996-06-28 | 2000-06-20 | Cavaliere Ved. Vesley; Renata Maria Anna | Enteral dietary compositions comprising a mixture of live lactic bacteria consisting of Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium infantis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59155321A (ja) * | 1983-02-25 | 1984-09-04 | Riyoushiyoku Kenkyukai | 整腸用製剤 |
| DE3406772A1 (de) * | 1984-02-24 | 1986-03-13 | Angelo 8137 Berg Schuler | Diaetetisches mittel zur herabsetzung der harnstoffkonzentration in koerperfluessigkeiten und seine herstellung |
| SE9002732D0 (sv) * | 1990-08-24 | 1990-08-24 | Kabivitrum Ab | Product containing growth factor |
| IT1254210B (it) | 1992-02-10 | 1995-09-14 | Simone Claudio De | Composizioni dietetiche e/o farmaceutiche a base di batteri lattici liofilizzati, loro preparazione e impiego |
| JP3623977B2 (ja) * | 1993-10-29 | 2005-02-23 | 明治乳業株式会社 | 潰瘍性大腸炎治療剤 |
| JP4852681B2 (ja) * | 1996-02-28 | 2012-01-11 | 雪印メグミルク株式会社 | 腸管内細胞溶解活性抑制剤 |
| US6203797B1 (en) * | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
| ID29150A (id) * | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| US6468525B1 (en) * | 1999-08-10 | 2002-10-22 | Renew Life, Inc. | Probiotic formulation |
| CA2407724A1 (en) | 2000-05-03 | 2001-11-08 | University Of Maryland, Baltimore | Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal |
| WO2002003879A1 (en) * | 2000-07-07 | 2002-01-17 | First Circle Medical, Inc. | Treatment of hiv using hyperthermia |
| JP2002186422A (ja) * | 2000-12-22 | 2002-07-02 | Morinaga Milk Ind Co Ltd | ラクトバシラス・ガッセリ及びビフィドバクテリウム属の菌を含有する非発酵食品 |
| FI109602B (fi) | 2001-01-25 | 2002-09-13 | Valio Oy | Probioottiyhdistelmä |
| US7550285B2 (en) * | 2001-02-06 | 2009-06-23 | Nestec S.A. | Endotoxin binding lactic acid bacteria and bifidobacteria |
| US20030017192A1 (en) * | 2001-06-19 | 2003-01-23 | Hanny Kanafani | Process for producing extended shelf-life ready-to-use milk compositions containing probiotics |
| US20030092163A1 (en) * | 2001-07-26 | 2003-05-15 | Collins John Kevin | Probiotic bifidobacterium strains |
| JP3364491B2 (ja) * | 2002-07-25 | 2003-01-08 | 株式会社アトリエ・ド・フロマージュ | ヨーグルトおよびその製造方法 |
-
2003
- 2003-01-31 SE SE0300245A patent/SE526711C2/sv not_active IP Right Cessation
-
2004
- 2004-01-27 CA CA2514659A patent/CA2514659C/en not_active Expired - Lifetime
- 2004-01-27 DE DE602004031079T patent/DE602004031079D1/de not_active Expired - Lifetime
- 2004-01-27 US US10/543,604 patent/US7947482B2/en active Active
- 2004-01-27 ZA ZA200505777A patent/ZA200505777B/en unknown
- 2004-01-27 EP EP04705562A patent/EP1587913B1/en not_active Expired - Lifetime
- 2004-01-27 CN CNB2004800088252A patent/CN100558883C/zh not_active Expired - Lifetime
- 2004-01-27 JP JP2006502776A patent/JP4540664B2/ja not_active Expired - Lifetime
- 2004-01-27 BR BRPI0407176A patent/BRPI0407176B8/pt not_active IP Right Cessation
- 2004-01-27 AU AU2004208084A patent/AU2004208084B2/en not_active Expired
- 2004-01-27 ES ES04705562T patent/ES2362496T3/es not_active Expired - Lifetime
- 2004-01-27 WO PCT/SE2004/000098 patent/WO2004067731A1/en not_active Ceased
- 2004-01-27 PL PL378435A patent/PL212096B1/pl unknown
- 2004-01-27 DK DK04705562.9T patent/DK1587913T3/da active
- 2004-01-27 AT AT04705562T patent/ATE496115T1/de not_active IP Right Cessation
- 2004-01-27 RU RU2005127331/13A patent/RU2352628C2/ru active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077504A (en) * | 1996-06-28 | 2000-06-20 | Cavaliere Ved. Vesley; Renata Maria Anna | Enteral dietary compositions comprising a mixture of live lactic bacteria consisting of Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium infantis |
| RU2112034C1 (ru) * | 1996-12-26 | 1998-05-27 | Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского | Штамм bifidobacterium infantis 73-15, используемый для приготовления бифидосодержащих бактерийных препаратов и продуктов лечебно-диетического питания |
Non-Patent Citations (1)
| Title |
|---|
| YANO Т. et al, Selective Growth and Mechanism of Related Enzymes of Bifidobacteria, Japanese Journal of Dairy and Food Science, v.39, № 6, 1990. * |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE496115T1 (de) | 2011-02-15 |
| PL212096B1 (pl) | 2012-08-31 |
| AU2004208084A1 (en) | 2004-08-12 |
| BRPI0407176B8 (pt) | 2021-05-25 |
| CN100558883C (zh) | 2009-11-11 |
| SE0300245L (sv) | 2004-08-01 |
| SE526711C2 (sv) | 2005-10-25 |
| CN1777670A (zh) | 2006-05-24 |
| US20060269533A1 (en) | 2006-11-30 |
| ZA200505777B (en) | 2007-12-27 |
| DE602004031079D1 (de) | 2011-03-03 |
| CA2514659A1 (en) | 2004-08-12 |
| ES2362496T3 (es) | 2011-07-06 |
| SE0300245D0 (sv) | 2003-01-31 |
| RU2005127331A (ru) | 2006-01-27 |
| BRPI0407176B1 (pt) | 2018-05-08 |
| EP1587913A1 (en) | 2005-10-26 |
| DK1587913T3 (da) | 2011-04-11 |
| EP1587913B1 (en) | 2011-01-19 |
| US7947482B2 (en) | 2011-05-24 |
| PL378435A1 (pl) | 2006-04-03 |
| JP4540664B2 (ja) | 2010-09-08 |
| CA2514659C (en) | 2014-07-08 |
| BRPI0407176A (pt) | 2006-02-07 |
| JP2006516405A (ja) | 2006-07-06 |
| AU2004208084B2 (en) | 2008-10-09 |
| WO2004067731A1 (en) | 2004-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4011532B2 (ja) | ビフィズス菌およびそれを含有する製剤 | |
| RU2352628C2 (ru) | Новые штаммы бифидобактерий, обладающие способностью продуцировать глутамин | |
| EP2498789A1 (en) | Probiotic bifidobacterium strain | |
| JP2005505298A (ja) | ラクトバシルス・ペントサス株を含む組成物およびそれらの使用 | |
| CN110373368B (zh) | 一种长双歧杆菌菌株zj1及其应用 | |
| CN114480231A (zh) | 一种抗幽门螺杆菌感染的罗伊氏乳杆菌及其应用 | |
| CN110023486B (zh) | 一种嗜酸乳杆菌及其培养方法和应用 | |
| CN110023484B (zh) | 一种假小链状双歧杆菌及其培养方法和应用 | |
| CN117327632B (zh) | 一种动物双歧杆菌及其应用 | |
| CN117305187B (zh) | 一种改善肠道健康状况的乳酸片球菌及其应用 | |
| CN117343880A (zh) | 一种唾液宿主关联乳杆菌及其应用 | |
| CN114574405B (zh) | 植物乳杆菌菌株wka86及其在制备防治口臭制品方面的用途与制品 | |
| CN117683670A (zh) | 一种植物乳植杆菌fmbl l23036 cnn、酸奶发酵剂、酸奶及其应用 | |
| CN119193436B (zh) | 一种缓解宠物腹泻和软便的复合益生菌及其应用 | |
| RU2735717C1 (ru) | Штамм Bifidobacterium bifidum, используемый в качестве пробиотика | |
| Ha et al. | In vitro assessment of probiotic potential and safety of two Lactobacillus gasseri strains isolated from mother's breast milk and infant's feces in Vietnam | |
| Al-Aabideen | Effect of Probiotic on Motility Factors and Swarming Phenomenon of Proteus mirabilis | |
| RU2491332C1 (ru) | Консорциум бифидобактерий для приготовления бактерийных препаратов и биологически активных добавок к пище, предназначенных для коррекции микрофлоры желудочно-кишечного тракта людей старше 14 лет, и способ его получения, биологически активная добавка к пище для коррекции микрофлоры желудочно-кишечного тракта людей старше 14 лет и бактериальный препарат для лечения дисбиотических состояний желудочно-кишечного тракта людей старше 14 лет | |
| RU2491334C1 (ru) | Консорциум бифидобактерий для приготовления бактерийных препаратов и биологически активных добавок к пище, предназначенных для коррекции микрофлоры желудочно-кишечного тракта детей в возрасте от 3-х до 14 лет, и способ его получения, биологически активная добавка к пище для коррекции микрофлоры желудочно-кишечного тракта детей от 3-х до 14 лет и бактериальный препарат для лечения дисбиотических состояний желудочно-кишечного тракта детей в возрасте от 3-х до 14 лет | |
| IE990033A1 (en) | Bifidobacterium longum infantis in the treatment of inflammatory bowel disease | |
| CN121086916A (zh) | 一株具有三重抗菌功效的植物乳植杆菌hl-pl05及其应用 | |
| EA043487B1 (ru) | Штамм bifidobacterium bifidum 8, используемый в качестве пробиотика | |
| KR20030075716A (ko) | 헬리코박터 파이로리(Ｈｅｌｃｏｂａｃｔｅｒｐｙｌｏｒｉ) 균주에 대해 항균효과가 있는 바실러스폴리퍼멘티쿠스(Ｂａｃｉｌｌｕｓｐｏｌｙｆｅｒｍｅｎｔｉｃｕｓ) ＳＣＤ 균주 또는폴리퍼멘티신(ｐｏｌｙｆｅｒｍｅｎｔｉｃｉｎ) ＳＣＤ가함유된 위장병 예방 및 치료용 조성물 | |
| Rajapaksha | Isolation, Identification and Characterization of Potential Probiotic Bacteria from Cow Colostrum from Sri Lankan Dairy Cattle Farms | |
| HK40010181A (en) | Lactobacillus gasseri, culture method therefor and application thereof |